Colorectal cancer is also known as the bowel cancer, colon cancer or rectal cancer. This type of cancer is the second leading cause of death in women and third in men. Colorectal cancer may be benign, or non-cancerous, or malignant. The symptoms shown by the patients suffering from colon cancer include changes in bowel habits, diarrhea or constipation, blood in stools that makes it look black in color. The colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery. The factors leading to the growth of the colorectal cancer market are the significantly rising incidences of colorectal cancer, easy access to the treatment for colorectal cancer, proposing guidelines for the treatment procedures.
Abbott Laboratories and F. Hoffmann-La Roche AG – Notable Market Players in Colorectal Cancer Market
Leading companies operating in the Colorectal Cancer market have undertaken various organic and inorganic growth strategies. The Colorectal Cancer market majorly comprises of Amgen Inc., Bruker Corporation, Epigenomics AG, Clinical Genomics Technologies Pty Ltd., VolitionRX Limited, Novigenix, F. Hoffmann-La Roche AG, Abbott, EDP Biotech, and Quest Diagnostics amongst others. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, and product approvals. Moreover, the market players have also deployed several utilized inorganic strategies, including mergers & acquisitions, partnerships, and collaborations.
Below are the major growth strategies undertaken by the players operating in the global Colorectal Cancer market:
| Year | News |
| Apr-2022 | Bruker launches a novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF fleX using AmberGen’s HiPLEX-IHC peptide code antibody probes in combination with unbiased lipidomics, glycomics and metabolomics tissue imaging. Improved product efficacy and new development will improve company’s product portfolio. |
| Jan-2022 | Amgen and Generate Biomedicines announced a research collaboration agreement to discover and develop protein therapeutics for five clinical targets across multiple therapeutic areas and multiple modalities. This collaboration will accelerate drug discovery efforts, generating novel protein sequences with optimal therapeutic properties. |
| Jan-2021 | Epigenomics AG was evaluating all options to challenge CMS’ decision to non-cover the Epi proColon test. A new blood-based test demonstrates performance characteristics that would satisfy the latest sensitivity and specificity requirements outlined in the final National Coverage Determination (NCD) issued by CMS. The impact of this has resulted in building on its expertise in liquid biopsy and DNA methylation biomarkers, Epigenomics AG has developed and validated a new colorectal cancer screening assay with clinical performance characteristics that meet the coverage criteria outlined in the final NCD |
